ASCO 2022: Fresh Data in the Setting of Metastatic Breast Cancer Treatment

Avan J. Armaghani, MD


June 03, 2022

Avan J. Armaghani, MD, surveys the host of research on metastatic breast cancer (mBC) to be presented at this year's ASCO conference, ranging from trials already established in their later stages to more recently launched lines of investigation.

The accumulating data represent the pledge of an expanded therapeutic space, Dr Armaghani implies, one in which agents formerly used against one cancer subtype may potentially extend to others, translating into an enriched array of options in the treatment of MBC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.